Biofrontera (BFRI) Cost of Revenue (2020 - 2025)
Biofrontera has reported Cost of Revenue over the past 6 years, most recently at $3.0 million for Q4 2025.
- For Q4 2025, Cost of Revenue fell 42.91% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $11.0 million, down 41.07%, while the annual FY2025 figure was $11.0 million, 41.08% down from the prior year.
- Cost of Revenue for Q4 2025 was $3.0 million at Biofrontera, up from $2.0 million in the prior quarter.
- Over five years, Cost of Revenue peaked at $17.5 million in Q4 2022 and troughed at -$1.4 million in Q4 2023.
- A 5-year average of $2.9 million and a median of $2.7 million in 2023 define the central range for Cost of Revenue.
- Biggest five-year swings in Cost of Revenue: surged 9554.7% in 2022 and later crashed 107.76% in 2023.
- Year by year, Cost of Revenue stood at $181000.0 in 2021, then surged by 9554.7% to $17.5 million in 2022, then crashed by 107.76% to -$1.4 million in 2023, then skyrocketed by 488.72% to $5.3 million in 2024, then plummeted by 42.91% to $3.0 million in 2025.
- Business Quant data shows Cost of Revenue for BFRI at $3.0 million in Q4 2025, $2.0 million in Q3 2025, and $2.6 million in Q2 2025.